Seminars in Hematology
Volume 44, Issue 3 , Pages 138-147 , July 2007

Hematopoietic Growth Factors in the Treatment of Acquired Bone Marrow Failure States

  • Judith C.W. Marsh

      Affiliations

    • Department of Haematology, St George’s Hospital/St George’s, University of London, London, UK.
    • Corresponding Author InformationAddress correspondence to Judith C.W. Marsh, MD, Department of Haematology, St George’s Hospital/St George’s, University of London, Cranmer Terrace, London, SW17 ORE, UK.
    • ,
  • Arnold Ganser

      Affiliations

    • Hannover Medical School, Hannover, Germany.
    • ,
  • Michael Stadler

      Affiliations

    • Hannover Medical School, Hannover, Germany.

References 

  1. Marsh JCW. Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Semin Hematol. 2000;37:81–90
  2. Matsuda A, Misumi M, Ishikawa M, Yagasaki F, Jinnai I, Bessho M, et al. Long-term improvement of anaemia in a patient with aplastic anaemia by short term administration of pegylated recombinant human megakaryocyte growth and development factor. Br J Haematol. 2004;125:818–819
  3. Marsh JCW, Socie G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P, et al. Haemopoietic growth factors in aplastic anaemia: A cautionary note. Lancet. 1994;344:172–173
  4. Philpott N, Scopes J, Marsh J, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anaemia bone marrow progenitor cells: Possible pathophysiological significance. Exp Haematol. 1995;23:1642–1648
  5. Bacigalupo A, Piaggio G, Podesta M, Van Lint MT, Valbonesi M, Lecari G, et al. Collection of peripheral blood haemopoietic progenitors (PBHP) from patients with severe aplastic anaemia (SAA) after prolonged administration of granulocyte colony stimulating factor. Blood. 1993;82:1410–1414
  6. Scopes J, Daly S, Atkinson R, Ball S, Gordon-Smith E, Gibson FM. Aplastic anaemia: Evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony stimulating factor in vitro. Blood. 1996;87:3179–3185
  7. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931–1934
  8. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol. 1999;107:330–334
  9. Bacigalupo A, Brand R, Oneto R, Socie G, Passweg J, Marsh J, et al. Treatment of acquired severe aplastic anaemia: Bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69–80
  10. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119:1075–1082
  11. Tichelli A: Presented at Bone Marrow Failure Scientific Symposium, Washington DC, October 17-19, 2005
  12. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009–1013
  13. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–2054
  14. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100:786–790
  15. Ohara A, Kojima S, Kobayashi R, Kosaka Y, Ohga S, Sugita K, et al. Ten year outcome of acquired aplastic anaemia children treated with antithymocyte globulin, cyclosporine with or without G-CSF. Blood. 2006;108:126;(abstr)
  16. Locasciulli A, Rambaldi A, Saracco P, Dufour C, Finelli C, Sica S, et al. Treatment of severe aplastic anaemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: A GITMO prospective randomised study. Haematologica. 2004;89:1054–1061
  17. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anaemia in children: A more severe disease predicts better survival. Blood. 2005;106:2102–2104
  18. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet. 2001;357:43–44
  19. Socie G, Mary JY, Schrezenemeier H, Marsh J, Bacigalupo A, Locasciulli A, et al. Granulocyte-stimulating factor and severe aplastic anaemia: A survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109:2794–2796
  20. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993;329:1152–1157
  21. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): A prospective comparison of four different regimens. Exp Hematol. 2006;34:826–831
  22. Ganser A. Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. Curr Opin Hematol. 1995;2:204–209
  23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  24. Casadevall N, et al. on the role of epoietin alpha in hematologic malignancies and myelodysplastic syndromes. Semin Oncol. 1998;25(suppl 7):12–18
  25. Verma A, List AF. Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep. 2005;4:429–435
  26. Thompson JA, Gilliland DG, Prchal JT, et al. GM/EPO MDS study group Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95:1175–1179
  27. Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood. 2003;101:1080–1086
  28. Sultana TA, Harada H, Ito K, Tanaka H, Kyo T, Kimura A. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol. 2003;121:63–75
  29. Awaya N, Uchida H, Miyakawa Y, Kinjo K, Matsushita H, Nakajima H, et al. Novel variant isoform of G-CSF receptor involved in induction of proliferation of FDCP-2 cells: Relevance to the pathogenesis of myelodysplastic syndrome. J Cell Physiol. 2002;191:327–335
  30. Szyper-Kravitz M, Uziel O, Shapiro H, Radnay J, Katz T, Rowe JM, et al. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol. 2003;120:329–336
  31. Takeshita A, Shinjo K, Naito K, Ohnishi K, Higuchi M, Ohno R. Erythropoietin receptor in myelodysplastic syndrome and leucemia. Leuk Lymphoma. 2002;43:261–264
  32. Bunworasate U, Arnouk H, Minderman H, O’Loughlin KL, Sait SN, Barcos M, et al. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood. 2001;98:3492–3494
  33. Sloand EM, Yong AS, Ramkissoon S, Solomou E, Bruno TC, Kim S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A. 2006;103:14483–14488
  34. Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom AM, Emanuelsson E, Jadersten M, et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: Concordance between in vitro and in vivo observations. Clin Cancer Res. 2005;11:6291–6299
  35. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106:803–811
  36. Rigolin GM, Porta MD, Ciccone M, Bugli AM, Bragotti LZ, Mauro E, et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol. 2004;126:501–507
  37. Pagliuca A, Carrington PA, Pettengell R, Tule S, Keidan J. Haemato-Oncology Task Force of the British Committee for Standards in Haematology: Guidelines on the use of colony-stimulating factors in haematological malignancies. Br J Haematol. 2003;123:22–33
  38. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  39. Heuser M, Ganser A. Colony-stimulating factors in the management of neutropenia and its complications. Ann Hematol. 2005;84:697–708
  40. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood. 1993;82:196a;(suppl 1, abstr)
  41. Becker PS. Growth factor priming in therapy of acute myelogenous leukemia. Curr Hematol Rep. 2004;3:413–418
  42. Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19:1929–1933
  43. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425
  44. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomised double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070–1074
  45. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients. Br J Haematol. 2002;118:174–180
  46. Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol. 2003;122:269–271
  47. Stasi R, Brunetti M, Terzoli E, Abruzzese E, Amadori S. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann Oncol. 2004;15:1684–1690
  48. Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84:167–176
  49. Clavio M, Nobili F, Balleari E, Girtler N, Ballerini F, Vitali P, et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: A preliminary report. Eur J Haematol. 2004;72:113–120
  50. Giraldo P, Nomdedeu B, Loscertales J, Requena C, de Paz R, Tormo M, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. 2006;107:2807–2816
  51. Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol. 2005;128:204–209
  52. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005;16:1921–1927
  53. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 2006;133:513–519
  54. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, et al. The Spanish Erythropathology Group Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes (Identification of a subgroup of responders). Haematologica. 1999;84:1058–1064
  55. Musto P, Sanpaolo G, D’Arena G, Scalzulli PR, Matera R, Falcone A, et al. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica. 2001;86:44–51
  56. Kasper C, Zahner J, Sayer HG. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol. 2002;128:497–502
  57. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood. 2004;104:321–327
  58. Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: Results from a randomized single-centre study. Ann Hematol. 2006;85:174–180
  59. Ganser A, Maurer A, Contzen C, Seipelt G, Ottmann OG, Schadeck-Gressel C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol. 1996;72:237–244
  60. Musto P, Falcone A, Sanpaolo G, Bodenizza C. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leuk Res. 2006;30:385–388
  61. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 2003;121:101–103
  62. Fragasso A, Mannarella C, Sacco A. Response to erythropoietin and moxifloxacin in a patient with myelodysplastic syndrome non-respondent to erythropoietin alone. Eur J Intern Med. 2002;13:521–523
  63. Tsiara SN, Chaidos A, Gouva M, Christou L, Panteli K, Kapsali E, et al. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone. J Exp Clin Cancer Res. 2004;23:47–52
  64. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, et al. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma. 1998;30:279–292
  65. Kizaki M, Miyakawa Y, Ikeda Y. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol. 2003;122:764–767
  66. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma. 2006;47:2049–2054
  67. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, et al. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005;29:649–652
  68. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344–351
  69. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037–1046
  70. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist. 2003;8:99–107
  71. Bowen D, Hyslop A, Keenan N, Groves M, Culligan D, Johnson P, et al. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica. 2006;91:709–710
  72. Sekeres MA, Fu AZ, Maciejewski JP, Golshayan AR, Kalaycio ME, Kattan MW. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer. 2007;109:1125–1132

PII: S0037-1963(07)00064-9

doi: 10.1053/j.seminhematol.2007.04.010

Seminars in Hematology
Volume 44, Issue 3 , Pages 138-147 , July 2007

Article Tools